Compare · CRWD vs ORPH
CRWD vs ORPH
Side-by-side comparison of CrowdStrike Holdings Inc. (CRWD) and Orphazyme A/S (ORPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRWD and ORPH operate in Computer Software: Prepackaged Software (Technology), so they compete in similar markets.
- CRWD is the larger of the two at $188.76B, about 1078.0x ORPH ($175.1M).
- CRWD has hit the wire 21 times in the past 4 weeks while ORPH has been quiet.
- CRWD has more recent analyst coverage (25 ratings vs 0 for ORPH).
- Company
- CrowdStrike Holdings Inc.
- Orphazyme A/S
- Price
- -
- -
- Market cap
- $188.76B
- $175.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Computer Software: Prepackaged Software
- Computer Software: Prepackaged Software
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 21
- 0
- Recent ratings
- 25
- 0
CrowdStrike Holdings Inc.
CrowdStrike Holdings, Inc. provides cloud-delivered solutions for endpoint and cloud workload protection in the United States, Australia, Germany, India, Israel, Romania, and the United Kingdom. It offers 19 cloud modules on its Falcon platform through a software as a service subscription-based model that covers various security markets, such as corporate workload security, security and vulnerability management, managed security services, IT operations management, threat intelligence services, identity protection, and log management. The company primarily sells its platform and cloud modules through its direct sales team. CrowdStrike Holdings, Inc. was incorporated in 2011 and is headquartered in Sunnyvale, California.
Orphazyme A/S
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
Latest CRWD
- PRESIDENT AND CEO Kurtz George sold $3,245,485 worth of shares (17,025 units at $190.63), decreasing direct ownership by 0.25% to 7,896,019 units (SEC Form 4)
- PRESIDENT AND CEO Kurtz George sold $1,934,734 worth of shares (10,000 units at $193.47), decreasing direct ownership by 0.13% to 7,916,019 units (SEC Form 4)
- PRESIDENT AND CEO Kurtz George sold $4,136,215 worth of shares (20,000 units at $206.81), decreasing direct ownership by 0.25% to 7,926,019 units (SEC Form 4)
- CrowdStrike’s Fal.Con 2026 Unites Cybersecurity’s Ecosystem to Secure the AI Revolution
- CrowdStrike Named the Frost Radar™ Leader in Cloud Workload Protection for Fourth Consecutive Time
- PRESIDENT AND CEO Kurtz George sold $4,344,054 worth of shares (20,000 units at $217.20), decreasing direct ownership by 0.25% to 7,946,019 units (SEC Form 4)
- The Hardest Part of Quantum-Proofing a Company Isn't the Encryption. It's Deciding Where to Start
- PRESIDENT AND CEO Kurtz George sold $4,461,739 worth of shares (20,000 units at $223.09), decreasing direct ownership by 0.25% to 7,966,019 units (SEC Form 4)
- CrowdStrike Expands Project QuiltWorks to SMBs, Extending Frontier AI Risk Protection to Organizations of Every Size
- PRESIDENT AND CEO Kurtz George sold $4,465,917 worth of shares (20,000 units at $223.30), decreasing direct ownership by 0.25% to 7,986,019 units (SEC Form 4)
Latest ORPH
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 20-F filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form NT 20-F/A filed by Orphazyme A/S (Amendment)
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form NT 20-F filed by Orphazyme A/S